FDA reclassifies blood gas monitors
This article was originally published in Clinica
The US FDA has announced the reclassification of three gas monitors. Both the cutaneous carbon dioxide monitor and those cutaneous oxygen monitors used on infants who are not under gas anaesthesia will be moved from class II requiring performance standards to class II requiring special controls, the agency announced in the December 13 Federal Register.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.